Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials

BACKGROUND: Conversion from calcineurin inhibitor (CNI) therapy to a mammalian target of rapamycin (mTOR) inhibitor following kidney transplantation may help to preserve graft function. Data are sparse, however, concerning the impact of conversion on posttransplant diabetes mellitus (PTDM) or the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommerer, Claudia, Witzke, Oliver, Lehner, Frank, Arns, Wolfgang, Reinke, Petra, Eisenberger, Ute, Vogt, Bruno, Heller, Katharina, Jacobi, Johannes, Guba, Markus, Stahl, Rolf, Hauser, Ingeborg A., Kliem, Volker, Wüthrich, Rudolf P., Mühlfeld, Anja, Suwelack, Barbara, Duerr, Michael, Paulus, Eva-Maria, Zeier, Martin, Porstner, Martina, Budde, Klemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146542/
https://www.ncbi.nlm.nih.gov/pubmed/30231851
http://dx.doi.org/10.1186/s12882-018-1031-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146542/
https://www.ncbi.nlm.nih.gov/pubmed/30231851
http://dx.doi.org/10.1186/s12882-018-1031-1

Ejemplares similares